193 related articles for article (PubMed ID: 25013217)
1. Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation.
Somigliana E; Peccatori FA; Filippi F; Martinelli F; Raspagliesi F; Martinelli I
Hum Reprod Update; 2014; 20(6):944-51. PubMed ID: 25013217
[TBL] [Abstract][Full Text] [Related]
2. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
3. Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.
Griesinger G
Semin Reprod Med; 2010 Nov; 28(6):493-9. PubMed ID: 21082508
[TBL] [Abstract][Full Text] [Related]
4. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
5. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
6. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
7. GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates.
Atkinson P; Koch J; Ledger WL
Aust N Z J Obstet Gynaecol; 2014 Dec; 54(6):581-5. PubMed ID: 25476811
[TBL] [Abstract][Full Text] [Related]
8. Long-acting gonadotropin-releasing hormone agonist trigger in fertility preservation cycles before chemotherapy.
Massarotti C; Stigliani S; Gazzo I; Lambertini M; Anserini P
ESMO Open; 2023 Aug; 8(4):101597. PubMed ID: 37421801
[TBL] [Abstract][Full Text] [Related]
9. Ovarian hyperstimulation syndrome and thrombotic events.
Mor YS; Schenker JG
Am J Reprod Immunol; 2014 Dec; 72(6):541-8. PubMed ID: 25146913
[TBL] [Abstract][Full Text] [Related]
10. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
[TBL] [Abstract][Full Text] [Related]
11. Risk of thrombosis in women with cancer undergoing controlled ovarian hyperstimulation for fertility preservation.
Melo VD; Liseth OY; Schmidt WM; Pruthi RK; Marshall AL; Shenoy CC
J Assist Reprod Genet; 2022 Dec; 39(12):2847-2856. PubMed ID: 36427171
[TBL] [Abstract][Full Text] [Related]
12. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
13. Arterial and venous complications after fertility treatment: A French nationwide cohort study.
Filipovic-Pierucci A; Gabet A; Deneux-Tharaux C; Plu-Bureau G; Olié V
Eur J Obstet Gynecol Reprod Biol; 2019 Jun; 237():57-63. PubMed ID: 31009860
[TBL] [Abstract][Full Text] [Related]
14. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger.
Fatemi HM; Garcia-Velasco J
Fertil Steril; 2015 Apr; 103(4):870-3. PubMed ID: 25724740
[TBL] [Abstract][Full Text] [Related]
15. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
[TBL] [Abstract][Full Text] [Related]
16. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
[TBL] [Abstract][Full Text] [Related]
17. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
[TBL] [Abstract][Full Text] [Related]
18. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G
Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation.
Pereira N; Kelly AG; Stone LD; Witzke JD; Lekovich JP; Elias RT; Schattman GL; Rosenwaks Z
Fertil Steril; 2017 Sep; 108(3):532-538. PubMed ID: 28865552
[TBL] [Abstract][Full Text] [Related]
20. Risk of ovarian hyperstimulation syndrome in women with malignancies undergoing treatment with long-acting gonadotropin-releasing hormone agonist after controlled ovarian hyperstimulation for fertility preservation: a systematic review.
Ingold C; Navarro PA; de Oliveira R; Barbosa CP; Bedoschi G
Ther Adv Reprod Health; 2023; 17():26334941231196545. PubMed ID: 37674690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]